LeMaitre Vascular (NASDAQ:LMAT) Price Target Raised to $79.00 at Barrington Research

LeMaitre Vascular (NASDAQ:LMAT) had its target price hoisted by Barrington Research from $69.00 to $79.00 in a research report sent to investors on Friday morning, Benzinga reports. The firm currently has an outperform rating on the medical instruments supplier’s stock.

Other equities analysts also recently issued research reports about the stock. StockNews.com downgraded shares of LeMaitre Vascular from a buy rating to a hold rating in a research note on Tuesday, April 16th. Stifel Nicolaus upgraded LeMaitre Vascular from a hold rating to a buy rating and lifted their price objective for the company from $59.00 to $75.00 in a research note on Friday, April 26th. Finally, KeyCorp initiated coverage on LeMaitre Vascular in a research note on Tuesday, February 6th. They issued a sector weight rating on the stock. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of Moderate Buy and a consensus target price of $73.83.

LeMaitre Vascular Stock Up 1.1 %

LMAT opened at $75.00 on Friday. The stock has a market cap of $1.68 billion, a PE ratio of 49.67, a PEG ratio of 2.99 and a beta of 0.88. The business has a 50 day moving average of $66.19 and a 200-day moving average of $59.04. LeMaitre Vascular has a 52 week low of $44.27 and a 52 week high of $76.24.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, beating the consensus estimate of $0.39 by $0.05. The business had revenue of $53.48 million during the quarter, compared to analyst estimates of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.27 earnings per share. Equities analysts anticipate that LeMaitre Vascular will post 1.77 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date of this dividend is Wednesday, May 15th. LeMaitre Vascular’s payout ratio is currently 42.38%.

Insider Buying and Selling

In other LeMaitre Vascular news, CFO Joseph P. Pellegrino, Jr. sold 36,967 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $69.76, for a total transaction of $2,578,817.92. Following the transaction, the chief financial officer now owns 6,452 shares in the company, valued at approximately $450,091.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Lawrence J. Jasinski sold 5,110 shares of LeMaitre Vascular stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total value of $344,925.00. Following the completion of the sale, the director now owns 5,309 shares of the company’s stock, valued at $358,357.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Joseph P. Pellegrino, Jr. sold 36,967 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $69.76, for a total value of $2,578,817.92. Following the completion of the transaction, the chief financial officer now directly owns 6,452 shares in the company, valued at approximately $450,091.52. The disclosure for this sale can be found here. In the last ninety days, insiders sold 114,036 shares of company stock worth $7,873,749. 10.79% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Several hedge funds and other institutional investors have recently made changes to their positions in LMAT. Quantbot Technologies LP grew its position in LeMaitre Vascular by 1,001.4% during the first quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock valued at $487,000 after buying an additional 6,669 shares during the period. Envestnet Portfolio Solutions Inc. purchased a new stake in shares of LeMaitre Vascular in the 1st quarter worth $206,000. Texas Permanent School Fund Corp raised its holdings in LeMaitre Vascular by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier’s stock worth $1,151,000 after purchasing an additional 225 shares during the period. Whitegate Investment Counselors Inc. bought a new position in LeMaitre Vascular in the 1st quarter worth $216,000. Finally, BNP Paribas Financial Markets lifted its position in LeMaitre Vascular by 135.6% during the first quarter. BNP Paribas Financial Markets now owns 22,917 shares of the medical instruments supplier’s stock valued at $1,521,000 after purchasing an additional 13,189 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.